查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1576098

血友病的全球市場的評估:各類型，不同治療，各類藥物，各治療法，各流通管道，各地區，機會，預測(2017年～2031年)

Hemophilia Market Assessment, By Type, By Treatment, By Drug Class, By Therapy, By Distribution Channel, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 231 Pages | 商品交期: 3-5個工作天內

價格

全球血友病市場規模預計將從 2023 年的 131.1 億美元增至 2031 年的 201.2 億美元，預計 2024 年至 2031 年的複合年增長率為 5.50%。由於盛行率的增加以及投資者和市場參與者興趣的增加，預計血友病市場需求將在預測期內呈指數級增長。

血友病是一種極為罕見的遺傳性疾病，由於體內缺乏凝血因子，血液凝固受到抑制。這種疾病是一種X連鎖隱性遺傳疾病，因此較常見於男性。此外，血友病治療市場的推動因素包括用於治療血友病的療法領域的發展、向標靶治療和聯合治療的範式轉變，以及由於認識的提高而提高的診斷率，預計該市場將以比預測更快的速度成長。此外，政府為消除血友病做出了重大努力，批准了用於治療血友病的產品，無論是藥物還是治療方法，從而補充了這種增長。 2024年4月，輝瑞宣布BEQVEZ（fidanacogene elaparvovec-dzkt）獲得美國食品藥物管理局（FDA）核准用於治療成人中度重度B型血友病。這包括目前正在使用 FIX 預防性治療的患者、曾發生危及生命的出血的患者、曾多次發生嚴重自發性出血的患者，以及在 FDA 批准的測試中顯示具有 AAVRh74var 衣殼中和抗體的患者。 BEQVEZ 是一種一次性治療，有可能讓 B 型血友病患者自行修復。

本報告提供全球血友病市場相關調查分析，提供市場規模與預測，市場動態，主要企業的形勢等資訊。

目錄

第1章 計劃的範圍和定義

第2章 調查手法

第3章 摘要整理

第4章 全球血友病市場預測(2017年～2031年)

  • 市場規模的分析與預測
    • 金額
  • 市場佔有率的分析與預測
    • 各類型
    • 不同治療
    • 各類藥物
    • 各治療法
    • 各流通管道
    • 各地區
    • 市場佔有率分析:各企業(金額)(前五名公司和其他 - 2023年)
  • 市場地圖分析(2023年)
    • 各類型
    • 不同治療
    • 各類藥物
    • 各治療法
    • 各流通管道
    • 各地區

第5章 北美的血友病市場預測(2017年～2031年)

  • 市場規模的分析與預測
    • 金額
  • 市場佔有率的分析與預測
    • 各類型
    • 不同治療
    • 各類藥物
    • 各治療法
    • 各流通管道
    • 佔有率:各國
  • 各國的市場評估
    • 美國的血友病市場預測(2017年～2031年)
    • 加拿大
    • 墨西哥

第6章 歐洲的血友病市場預測(2017年～2031年)

  • 德國
  • 法國
  • 義大利
  • 英國
  • 俄羅斯
  • 荷蘭
  • 西班牙
  • 波蘭

第7章 亞太地區的血友病市場預測(2017年～2031年)

  • 印度
  • 中國
  • 日本
  • 澳洲
  • 越南
  • 韓國
  • 印尼
  • 菲律賓

第8章 南美的血友病市場預測(2017年～2031年)

  • 巴西
  • 阿根廷

第9章 中東·非洲的血友病市場預測(2017年～2031年)

  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非
  • 以色列

第10章 供需分析

第11章 價值鏈分析

第12章 波特的五力分析

第13章 大環境分析

第14章 價格分析

第15章 市場動態

  • 推動市場要素
  • 市場課題

第16章 市場趨勢與發展

第17章 法規結構和革新

  • 臨床試驗
  • 法規當局的認證

第18章 專利形勢

第19章 案例研究

第20章 競爭情形

  • 市場前五名領導者企業的競爭矩陣
  • 前五名公司的SWOT分析
  • 前十大主要企業的形勢
    • Takeda Pharmaceutical Company Limited
    • CSL Behring
    • Pfizer, Inc.
    • Bayer AG
    • BioMarin Pharmaceutical Inc.
    • Baxter International Inc.
    • Sanofi S.A.
    • F. Hoffmann La-Roche Ltd.
    • Novo Nordisk A/S
    • Octapharma AG

第21章 策略性推薦

第22章 本公司相關資料，免責聲明

Product Code: MX12145

Global hemophilia market is projected to witness a CAGR of 5.50% during the forecast period 2024-2031, growing from USD 13.11 billion in 2023 to USD 20.12 billion in 2031. The market demand for hemophilia is anticipated to thrive drastically in the forecast years due to rising prevalence and the growing interest of investors and market players.

Hemophilia is a very rare genetic disorder where blood clotting gets impeded due to the lack of blood clotting factors present in the body. The foremost incidence of this disease takes place among males because this is an X-linked recessive disorder. Further catalyzed by developments in the therapy areas used for the treatment of hemophilia, a paradigm shift towards targeted and combination therapy, and a higher diagnosis rate on account of rising awareness, the market for hemophilia therapeutics will probably boom at a faster rate during the forecast period, with the growing disease burden of this disease. Further, this growth is complemented by significant initiatives taken by the government to eradicate hemophilia by approving the products used in treating hemophilia, whether it be pharmaceuticals or therapies. In April 2024, Pfizer Inc. stated that it received approval from the U.S. Food and Drug Administration for BEQVEZ (fidanacogene elaparvovec-dzkt) to treat adults with moderate to severe hemophilia B. It includes those who currently use FIX prophylaxis therapy, have had life-threatening hemorrhages, repeated, serious spontaneous bleeding episodes, or do not have neutralizing antibodies to AAVRh74var capsid as indicated by an FDA-approved test. BEQVEZ is a one-time treatment that might enable people with hemophilia B to make FIX themselves, as opposed to now, receiving regular intravenous infusions of FIX several times a week or month.

High Disease Burden of Hemophilia to Drive Market Growth

The global disease burden is relatively high and rising. Inheritance patterns, consanguinity, and an increasing diagnosis rate contribute to the high prevalence. Usually, a high disease burden and high demand for therapeutic products lead to higher diagnosis prevalence. As the disease burden of hemophilia increases, the demand for the hemophilia market is expected to rise. Awareness and diagnosis increase with the rise in prevalence, giving rise to the development of technologies for treatment, genetic engineering, and recombinant factor concentrates. These innovations improve patient outcomes and fuel market growth as they find widespread acceptance. Global initiatives, including the World Federation of Hemophilia and the World Health Organization (WHO), are ongoing to reduce the disease burden and create adequate awareness. For instance, if one looks at the results of the Annual Global Survey by the World Federation of Hemophilia published in October 2023, the total number of identified patients with hemophilia globally was 257,146 compared to 241,535 in 2020, thus increasing 6.46% over two years.

Advancements in Gene Therapy to Lead to Market Growth

Advancements in gene therapy are significantly driving market growth in the hemophilia market. Recent clinical trials utilizing adeno-associated viral (AAV) vectors have demonstrated stable and long-term expression of these factors, leading to significant reductions in spontaneous bleeding and the need for regular infusions. The market is further bolstered by biopharmaceutical companies' ongoing research and development efforts, which are focused on optimizing gene delivery methods and improving treatment efficacy. In June 2023, BioMarin Pharmaceutical Inc. announced that the United States Food and Drug Administration (FDA) approved ROCTAVIAN (valoctocogene roxaparvovec-rvox) gene therapy for the treatment of adults with severe hemophilia A. This type of hemophilia is characterized by congenital factor VIII (FVIII) deficiency with FVIII activity less than 1 IU/dL and without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test. The one-time, single-dose infusion is the first approved gene therapy for severe hemophilia A in the United States. Also, ROCTAVIAN was first approved by the European Medicines Agency in August 2022.

Hemophilia A Segment to Dominate the Hemophilia Market Share

The dominance of Hemophilia A in the hemophilia treatment market can be attributed to several key factors. Hemophilia A accounts for approximately 74.16% of all hemophilia cases globally, making it the most prevalent type of genetic disorder. This significant patient population drives the demand for targeted therapies and treatments, ensuring that Hemophilia A remains the focal point for pharmaceutical companies and healthcare providers. As per the Annual Global Survey conducted by the World Federation of Hemophilia, published in October 2023, out of 257,146 identified hemophilia patients worldwide, 208,957 were suffering from hemophilia A while 42,203 were suffering from hemophilia B and the rest were suffering from unknown type. It indicates that hemophilia A is 4.9 times more prevalent than hemophilia B. Thus, the combination of high prevalence, continuous innovation in treatment, and substantial financial implications positions Hemophilia A as the leading segment in the hemophilia market.

North America to Dominate the Hemophilia Market Share

North America leads the hemophilia market due to several interrelated factors that improve treatment accessibility and innovation. The presence of established healthcare infrastructure, specialized hemophilia treatment centers, and significant financial support for research and development further bolsters market growth. Substantial government initiatives and funding have been directed toward gene therapy and other innovative treatments, improving patient outcomes and expanding treatment options. According to the Canadian Hemophilia Society, about 3,900 Canadians are affected by hemophilia A, and about 800 Canadians suffer from hemophilia B. Similarly, the data of the National Bleeding Disorders Foundation quotes that hemophilia occurs in approximately 1 in 5,617 live male births, resulting in 30,000-33,000 males with hemophilia in the United States.

Future Market Scenario (2024 - 2031F)

Favorable reimbursement and health insurance coverage for hemophilia treatment are shaping the future market growth of the hemophilia market. The growing popularity of health insurance, especially in developing countries, enables more patients to afford expensive hemophilia treatments. Reimbursement policies are expanding to include newer therapies, such as gene therapy for hemophilia treatment. In November 2023, BioMarin Pharmaceutical Inc. reached an agreement with the German National Association of Statutory Health Insurance Funds (GKV-SV) regarding the reimbursement amount for ROCTAVIAN (valoctocogene roxaparvovec-rvox) for individuals with severe hemophilia A. It marks the first gene therapy for hemophilia to establish a set federal price in Germany. ROCTAVIAN provides value to patients and the German healthcare system as a one-time, single-dose therapy administered through an intravenous infusion lasting 3-4 hours, priced at USD 31,274.25 per vial.

Key Players Landscape and Outlook

The hemophilia market is primarily dominated by players such as Novo Nordisk A/S and Baxter International Inc. Market activity reported in recent years includes business agreements, collaborations, and regulatory approvals of products. The market fosters several smaller players as well, which operate through partnerships with other players to cater to a larger market.

In June 2024, 2seventy bio, Inc. announced the completion of an asset purchase agreement by Novo Nordisk A/S. Under the terms of the agreement, Novo Nordisk acquired the Hemophilia A program and the rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for autologous or allogeneic cell therapies to treat autoimmune disease. The 2seventy bio team currently involved in the program will join Novo Nordisk and continue to advance the technology.

In March 2024, ReciBioPharm AB entered into a collaboration agreement with GeneVentiv Therapeutics, Inc., a preclinical gene therapy company, to extend the development of a universal gene therapy for hemophilia based on adeno-associated virus (AAV). This therapy is reportedly the first of its kind designed to treat hemophilia patients with inhibitors. GeneVentiv's GENV-HEM (AAV8.FVa) is a single infusion, universal AAV-based gene therapy for all types of hemophilia. ReciBioPharm intends to expedite the development by leveraging its AAV manufacturing platform at its Watertown facility in Massachusetts.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Hemophilia Market Outlook, 2017-2031F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Hemophilia A
      • 4.2.1.2. Hemophilia B
      • 4.2.1.3. Hemophilia C
    • 4.2.2. By Treatment
      • 4.2.2.1. On-demand Treatment
      • 4.2.2.2. Prophylactic Treatment
    • 4.2.3. By Drug Class
      • 4.2.3.1. Clotting Factors
        • 4.2.3.1.1. Recombinant Factor Concentrates
        • 4.2.3.1.2. Plasma-derived Factor Concentrates
      • 4.2.3.2. Monoclonal Antibodies
      • 4.2.3.3. Antidiuretic Drugs
      • 4.2.3.4. Antihemorrhagic Drugs
      • 4.2.3.5. Aminocaproic Acid
      • 4.2.3.6. Antifibrinolytic Agents
    • 4.2.4. By Therapy
      • 4.2.4.1. Replacement Therapy
      • 4.2.4.2. Immune Tolerance Induction (ITI) Therapy
      • 4.2.4.3. Gene Therapy
    • 4.2.5. By Distribution Channel
      • 4.2.5.1. Hospital Pharmacies
      • 4.2.5.2. Retail Pharmacies
      • 4.2.5.3. Specialty Centers
    • 4.2.6. By Region
      • 4.2.6.1. North America
      • 4.2.6.2. Europe
      • 4.2.6.3. Asia-Pacific
      • 4.2.6.4. South America
      • 4.2.6.5. Middle East and Africa
    • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2023)
  • 4.3. Market Map Analysis, 2023
    • 4.3.1. By Type
    • 4.3.2. By Treatment
    • 4.3.3. By Drug Class
    • 4.3.4. By Therapy
    • 4.3.5. By Distribution Channel
    • 4.3.6. By Region

5. North America Hemophilia Market Outlook, 2017-2031F*

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Type
      • 5.2.1.1. Hemophilia A
      • 5.2.1.2. Hemophilia B
      • 5.2.1.3. Hemophilia C
    • 5.2.2. By Treatment
      • 5.2.2.1. On-demand Treatment
      • 5.2.2.2. Prophylactic Treatment
    • 5.2.3. By Drug Class
      • 5.2.3.1. Clotting Factors
        • 5.2.3.1.1. Recombinant Factor Concentrates
        • 5.2.3.1.2. Plasma-derived Factor Concentrates
      • 5.2.3.2. Monoclonal Antibodies
      • 5.2.3.3. Antidiuretic Drugs
      • 5.2.3.4. Antihemorrhagic Drugs
      • 5.2.3.5. Aminocaproic Acid
      • 5.2.3.6. Antifibrinolytic Agents
    • 5.2.4. By Therapy
      • 5.2.4.1. Replacement Therapy
      • 5.2.4.2. Immune Tolerance Induction (ITI) Therapy
      • 5.2.4.3. Gene Therapy
    • 5.2.5. By Distribution Channel
      • 5.2.5.1. Hospital Pharmacies
      • 5.2.5.2. Retail Pharmacies
      • 5.2.5.3. Specialty Centers
    • 5.2.6. By Country Share
      • 5.2.6.1. United States
      • 5.2.6.2. Canada
      • 5.2.6.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Hemophilia Market Outlook, 2017-2031F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share Analysis & Forecast
        • 5.3.1.2.1. By Type
          • 5.3.1.2.1.1. Hemophilia A
          • 5.3.1.2.1.2. Hemophilia B
          • 5.3.1.2.1.3. Hemophilia C
        • 5.3.1.2.2. By Treatment
          • 5.3.1.2.2.1. On-demand Treatment
          • 5.3.1.2.2.2. Prophylactic Treatment
        • 5.3.1.2.3. By Drug Class
          • 5.3.1.2.3.1. Clotting Factors
          • 5.3.1.2.3.1.1. Recombinant Factor Concentrates
          • 5.3.1.2.3.1.2. Plasma-derived Factor Concentrates
          • 5.3.1.2.3.2. Monoclonal Antibodies
          • 5.3.1.2.3.3. Antidiuretic Drugs
          • 5.3.1.2.3.4. Antihemorrhagic Drugs
          • 5.3.1.2.3.5. Aminocaproic Acid
          • 5.3.1.2.3.6. Antifibrinolytic Agents
        • 5.3.1.2.4. By Therapy
          • 5.3.1.2.4.1. Replacement Therapy
          • 5.3.1.2.4.2. Immune Tolerance Induction (ITI) Therapy
          • 5.3.1.2.4.3. Gene Therapy
        • 5.3.1.2.5. By Distribution Channel
          • 5.3.1.2.5.1. Hospital Pharmacies
          • 5.3.1.2.5.2. Retail Pharmacies
          • 5.3.1.2.5.3. Specialty Centers
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Hemophilia Market Outlook, 2017-2031F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Poland

7. Asia-Pacific Hemophilia Market Outlook, 2017-2031F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Hemophilia Market Outlook, 2017-2031F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Hemophilia Market Outlook, 2017-2031F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa
  • 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

  • 17.1. Clinical Trials
  • 17.2. Regulatory Approvals

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. Takeda Pharmaceutical Company Limited
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. CSL Behring
    • 20.3.3. Pfizer, Inc.
    • 20.3.4. Bayer AG
    • 20.3.5. BioMarin Pharmaceutical Inc.
    • 20.3.6. Baxter International Inc.
    • 20.3.7. Sanofi S.A.
    • 20.3.8. F. Hoffmann La-Roche Ltd.
    • 20.3.9. Novo Nordisk A/S
    • 20.3.10. Octapharma AG

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 3. Global Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 4. Global Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 5. Global Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 6. Global Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 7. Global Hemophilia Market Share (%), By Region, 2017-2031F
  • Figure 8. North America Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 10. North America Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 11. North America Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 12. North America Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 13. North America Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 14. North America Hemophilia Market Share (%), By Country, 2017-2031F
  • Figure 15. United States Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 17. United States Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 18. United States Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 19. United States Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 20. United States Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 21. Canada Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 23. Canada Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 24. Canada Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 25. Canada Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 26. Canada Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 27. Mexico Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 29. Mexico Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 30. Mexico Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 31. Mexico Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 32. Mexico Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 33. Europe Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 35. Europe Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 36. Europe Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 37. Europe Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 38. Europe Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 39. Europe Hemophilia Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 42. Germany Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 43. Germany Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 44. Germany Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 45. Germany Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 46. France Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 48. France Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 49. France Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 50. France Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 51. France Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 52. Italy Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 54. Italy Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 55. Italy Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 56. Italy Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 57. Italy Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 58. United Kingdom Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 60. United Kingdom Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 61. United Kingdom Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 62. United Kingdom Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 63. United Kingdom Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 64. Russia Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 66. Russia Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 67. Russia Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 68. Russia Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 69. Russia Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 70. Netherlands Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 72. Netherlands Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 73. Netherlands Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 74. Netherlands Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 75. Netherlands Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 76. Spain Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 78. Spain Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 79. Spain Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 80. Spain Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 81. Spain Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 82. Turkey Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 84. Turkey Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 85. Turkey Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 86. Turkey Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 87. Turkey Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 88. Poland Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 90. Poland Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 91. Poland Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 92. Poland Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 93. Poland Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 94. South America Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 96. South America Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 97. South America Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 98. South America Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 99. South America Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 100. South America Hemophilia Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 103. Brazil Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 104. Brazil Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 105. Brazil Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 106. Brazil Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 107. Argentina Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 109. Argentina Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 110. Argentina Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 111. Argentina Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 112. Argentina Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 113. Asia-Pacific Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 115. Asia-Pacific Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 116. Asia-Pacific Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 117. Asia-Pacific Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 118. Asia-Pacific Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 119. Asia-Pacific Hemophilia Market Share (%), By Country, 2017-2031F
  • Figure 120. India Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 122. India Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 123. India Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 124. India Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 125. India Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 126. China Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 128. China Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 129. China Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 130. China Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 131. China Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 132. Japan Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 134. Japan Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 135. Japan Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 136. Japan Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 137. Japan Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 138. Australia Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 140. Australia Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 141. Australia Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 142. Australia Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 143. Australia Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 144. Vietnam Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 146. Vietnam Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 147. Vietnam Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 148. Vietnam Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 149. Vietnam Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 150. South Korea Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 152. South Korea Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 153. South Korea Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 154. South Korea Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 155. South Korea Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 156. Indonesia Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 158. Indonesia Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 159. Indonesia Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 160. Indonesia Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 161. Indonesia Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 162. Philippines Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 164. Philippines Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 165. Philippines Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 166. Philippines Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 167. Philippines Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 168. Middle East & Africa Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 170. Middle East & Africa Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 171. Middle East & Africa Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 172. Middle East & Africa Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 173. Middle East & Africa Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 174. Middle East & Africa Hemophilia Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 177. Saudi Arabia Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 178. Saudi Arabia Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 179. Saudi Arabia Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 180. Saudi Arabia Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 181. UAE Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 183. UAE Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 184. UAE Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 185. UAE Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 186. UAE Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 187. South Africa Hemophilia Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa Hemophilia Market Share (%), By Type, 2017-2031F
  • Figure 189. South Africa Hemophilia Market Share (%), By Treatment, 2017-2031F
  • Figure 190. South Africa Hemophilia Market Share (%), By Drug Class, 2017-2031F
  • Figure 191. South Africa Hemophilia Market Share (%), By Therapy, 2017-2031F
  • Figure 192. South Africa Hemophilia Market Share (%), By Distribution Channel, 2017-2031F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 198. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023